Trump Signs Executive Order on Prescription Drug Prices
President Donald Trump issued an executive order on Monday aimed at forcing pharmaceutical companies to reduce prescription drug prices, warning them of potential repercussions from the federal government. The order is broader than just government programs, essentially involving price management.
Commenting on this, Cannon noted that similar government price controls have led to shortages in the housing sector, often referred to as rent control. He cited examples like price caps on food and price gouging laws following natural disasters, suggesting that price controls could lead to similar issues in the pharmaceutical industry.
In simple terms, price control means government intervention to set allowable charges for various goods and services within a free-market framework. While some consumers might benefit from such price management, history shows it often has limited impact. For instance, former President Nixon’s attempts in the 1970s to manage prices and wages faced significant challenges.
Under Trump’s new order, the Department of Health and Human Services is tasked with establishing price targets for drug manufacturers. Cannon highlighted that this order doesn’t just pertain to government prices; it reaches into the free market and the private sector, as well.
If companies fail to comply, enforcement actions may be taken by the Department of Justice and the Federal Trade Commission against anti-competitive practices. Additionally, Trump proposed aligning U.S. drug prices with the lowest prices other developed countries pay.
“The principle is quite straightforward,” Trump stated. “Americans should pay the same prices for medications as those in Europe.” He further claimed that some prescription drug prices could potentially decrease by as much as 50-90%.
Contradicting the notion of price management, the White House asserted that if Americans had a truly competitive market, they wouldn’t be paying significantly more for the same medications compared to Europeans. A spokesperson criticized the situation as one where U.S. citizens end up subsidizing healthcare costs in other nations.
According to the Department of Health and Human Services, prescription drug prices have surged, with a reported increase of over 15% between January 2022 and January 2023, with a significant number of drugs experiencing price hikes surpassing inflation rates.
Pharmaceutical industry representatives argued that the executive order could harm U.S. patients. PhRMA president Stephen J. UBL cautioned that importing price standards from countries with socialist policies could result in fewer treatments available, endangering countless patients.
In April, Trump had already signed an executive order addressing Medicare drug prices, which aimed to standardize payments for prescription drugs regardless of treatment location, with potential price reductions for patients reaching up to 60%.
Overall, the administration continues to push for reforms aimed at bringing down significant drug costs in the country, hoping to create a fairer pricing landscape for American consumers.
